Drug Trial Radar · NCT04750226
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Feb 18, 2021
Primary completion
Apr 27, 2026
Study completion Apr 27, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
Conditions
- Parkinson's Disease (PD)
Interventions
ABBV-951Drug
Solution for continuous subcutaneous infusion (CSCI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Event (AEs)Time frame: Up to Week 96
- Percentage of Participants with AEs of Special Interest (AESIs)Time frame: Up to Week 96
- Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
- Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
- Change From Baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up To Week 96
- Change From Baseline in Impulsive-Compulsive Disorders and related behaviors as assessed in Parkinson's Disease- Rating Scale (QUIP-RS)Time frame: Up To Week 96
- Change From Baseline in Cognitive Impairment as Assessed by the Mini-Mental State Examination (MMSE)Time frame: Up To Week 96
- Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed.Time frame: Up to Week 96
- Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements like Systolic and Diastolic Blood Pressure will be AssessedTime frame: Up to Week 96
- Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to Week 96
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 217814
Birmingham, Alabama
Usa Mitchell Cancer Institute /ID# 218467
Mobile, Alabama
Xenoscience, Inc /ID# 222515
Phoenix, Arizona
Muhammad Ali Parkinson Center /ID# 218609
Phoenix, Arizona
Movement Disorders Center of Arizona /ID# 218471
Scottsdale, Arizona
Neuro Pain Research Center /ID# 217720
Fresno, California
Loma Linda University Medical /ID# 217724
Loma Linda, California
University of California, Los Angeles /ID# 218460
Los Angeles, California
SC3 Research Group - Pasadena /ID# 223018
Pasadena, California
University of California, San /ID# 218595
San Diego, California
Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 218607
West Hollywood, California
University of Colorado Hospital /ID# 218486
Aurora, Colorado
Alpine Clinical Research Center /ID# 218461
Boulder, Colorado
Denver Neurological Research, LLC /ID# 217811
Denver, Colorado
CenExel Rocky Mountain Clinical Research, LLC /ID# 217731
Englewood, Colorado
Georgetown University Hospital /ID# 218599
Washington D.C., District of Columbia
Visionary Investigators Network - Miami /ID# 217726
Miami, Florida
Renstar Medical Research /ID# 217837
Ocala, Florida
Neurology Associates Ormond Beach /ID# 217800
Ormond Beach, Florida
Parkinson's Disease Treatment Center of Southwest Florida /ID# 222679
Port Charlotte, Florida
University of South Florida- Neuroscience Institute /ID# 218481
Tampa, Florida
Premiere Research Institute - Palm Beach /ID# 218743
West Palm Beach, Florida
Rush University Medical Center /ID# 217807
Chicago, Illinois
University of Chicago Medical Center /ID# 218611
Chicago, Illinois
St Elizabeth's Medical Center - Brighton /ID# 223082
Brighton, Massachusetts
St. Lukes Hosp. of Kansas City /ID# 218604
Kansas City, Missouri
Washington University-School of Medicine /ID# 217723
St Louis, Missouri
Global Neurosciences Institute /ID# 218472
Lawrenceville, New Jersey
Northwell Health /ID# 218600
Lake Success, New York
M3 Wake Research - Raleigh /ID# 218482
Raleigh, North Carolina
The Orthopedic Foundation /ID# 218608
New Albany, Ohio
The Movement Disorder Clinic of Oklahoma /ID# 218580
Tulsa, Oklahoma
Legacy Medical Group - Neurology /ID# 217804
Portland, Oregon
University of Pennsylvania /ID# 218605
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital /ID# 218594
Philadelphia, Pennsylvania
Prisma Health-Upstate /ID# 217803
Greenville, South Carolina
Coastal Neurology /ID# 222893
Port Royal, South Carolina
KCA Neurology - Franklin /ID# 222811
Franklin, Tennessee
Vanderbilt University Medical Center /ID# 217722
Nashville, Tennessee
St. David's Healthcare Partnership, L.P., LLP /ID# 248148
Austin, Texas
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.